Korro Bio (FREQ) Stock Forecast, Price Target & Predictions
FREQ Stock Forecast
Korro Bio stock forecast is as follows: an average price target of $7.00 (represents a 2236.45% upside from FREQ’s last price of $0.30) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
FREQ Price Target
The average price target for Korro Bio (FREQ) is $7.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 2236.45% upside from FREQ's last price of $0.30.
FREQ Analyst Ratings
According to 2 Wall Street analysts, Korro Bio's rating consensus is 'Buy'. The analyst rating breakdown for FREQ stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Korro Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | Chardan Capital | $7.00 | $2.04 | 243.14% | 2236.45% |
The latest Korro Bio stock forecast, released on Dec 08, 2022 by Chardan Capital company, set a price target of $7.00, which represents a 243.14% increase from the stock price at the time of the forecast ($2.04), and a 2236.45% increase from FREQ last price ($0.30).
Korro Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.30 | $0.30 | $0.30 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Korro Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Korro Bio's last price of $0.30. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 14, 2023 | Cowen & Co. | - | Outperform | Initialise |
| Dec 08, 2022 | Chardan Capital | - | Buy | Initialise |
Korro Bio's last stock rating was published by Cowen & Co. on Feb 14, 2023. The company Initialise its FREQ rating from "null" to "Outperform".
Korro Bio Financial Forecast
Korro Bio Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $-28.11M | - | $9.42M | $4.65M | $9.95M | $11.25M | $8.52M | $7.26M | $4.71M | $24.24M |
| Avg Forecast | - | - | - | - | - | $15.19M | $6.27M | $31.00M | $16.25M | $16.25M | $6.71M | $3.70M | $14.46M | $14.46M | $8.07M | $7.72M | $22.46M | $22.46M |
| High Forecast | - | - | - | - | - | $18.23M | $7.53M | $25.87M | $13.56M | $19.50M | $5.60M | $3.09M | $12.07M | $17.35M | $6.74M | $6.44M | $18.74M | $26.95M |
| Low Forecast | - | - | - | - | - | $12.15M | $5.02M | $36.13M | $18.94M | $13.00M | $7.82M | $4.31M | $16.85M | $11.57M | $9.41M | $9.00M | $26.17M | $17.96M |
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | -1.73% | - | 1.40% | 1.26% | 0.69% | 0.78% | 1.06% | 0.94% | 0.21% | 1.08% |
Korro Bio's average Quarter revenue forecast for Mar 22 based on 10 analysts is $31.00M, with a low forecast of $36.13M, and a high forecast of $25.87M. FREQ's average Quarter revenue forecast represents a -210.29% decrease compared to the company's last Quarter revenue of $-28.11M (Dec 21).
Korro Bio EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| EBITDA | - | - | - | - | $-12.66M | $-18.62M | $-20.39M | $-22.47M | $63.24M | $-24.23M | $-16.54M | $-19.77M | $-9.87M | $-5.03M | $-5.77M | $-4.66M | $-5.27M | $-361.00K |
| Avg Forecast | - | - | - | - | - | $-16.29M | $-15.16M | $-21.04M | $-1.52M | $-17.42M | $-16.22M | $-14.69M | $-1.35M | $-6.46M | $-5.45M | $-4.93M | $-2.09M | $-334.45K |
| High Forecast | - | - | - | - | - | $-13.03M | $-12.13M | $-16.84M | $-1.26M | $-13.94M | $-12.97M | $-11.75M | $-1.13M | $-5.17M | $-4.36M | $-3.95M | $-1.75M | $-267.56K |
| Low Forecast | - | - | - | - | - | $-19.55M | $-18.20M | $-25.25M | $-1.77M | $-20.91M | $-19.46M | $-17.63M | $-1.57M | $-7.75M | $-6.54M | $-5.92M | $-2.44M | $-401.35K |
| Surprise % | - | - | - | - | - | 1.14% | 1.34% | 1.07% | -41.73% | 1.39% | 1.02% | 1.35% | 7.32% | 0.78% | 1.06% | 0.94% | 2.52% | 1.08% |
10 analysts predict FREQ's average Quarter EBITDA for Mar 22 to be $-21.04M, with a high of $-16.84M and a low of $-25.25M. This is -133.28% lower than Korro Bio's previous annual EBITDA (Dec 21) of $63.24M.
Korro Bio Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| Net Income | - | - | - | - | $-11.61M | $-19.55M | $-21.29M | $-23.39M | $63.10M | $-25.16M | $-17.66M | $-20.38M | $-10.23M | $-5.34M | $-6.03M | $-4.91M | $-5.49M | $-575.00K |
| Avg Forecast | $56.91M | $49.57M | $58.21M | $-10.71M | $-12.18M | $-16.92M | $-16.18M | $-21.90M | $-20.31M | $-18.09M | $-17.31M | $-15.14M | $-11.82M | $-6.87M | $-5.69M | $-5.20M | $25.11M | $-532.72K |
| High Forecast | $45.14M | $39.32M | $46.16M | $-8.49M | $-12.18M | $-13.53M | $-12.95M | $-17.52M | $-16.11M | $-14.48M | $-13.85M | $-12.11M | $-9.37M | $-5.49M | $-4.55M | $-4.16M | $19.91M | $-426.18K |
| Low Forecast | $68.69M | $59.83M | $70.25M | $-12.92M | $-14.03M | $-20.30M | $-19.42M | $-26.28M | $-24.51M | $-21.71M | $-20.77M | $-18.17M | $-14.26M | $-8.24M | $-6.83M | $-6.24M | $30.30M | $-639.26K |
| Surprise % | - | - | - | - | 0.95% | 1.16% | 1.32% | 1.07% | -3.11% | 1.39% | 1.02% | 1.35% | 0.87% | 0.78% | 1.06% | 0.94% | -0.22% | 1.08% |
Korro Bio's average Quarter net income forecast for Mar 22 is $-21.90M, with a range of $-26.28M to $-17.52M. FREQ's average Quarter net income forecast represents a -134.71% decrease compared to the company's last Quarter net income of $63.10M (Dec 21).
Korro Bio SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| SG&A | - | - | - | - | $10.11M | $8.56M | $8.00M | $9.48M | $-28.53M | $9.33M | $9.50M | $9.74M | $9.16M | $6.51M | $5.96M | $6.25M | $5.00M | $20.27M |
| Avg Forecast | - | - | - | - | - | $6.27M | $5.94M | $8.88M | $15.38M | $6.71M | $6.35M | $3.50M | $13.69M | $8.37M | $5.63M | $6.62M | $21.26M | $18.78M |
| High Forecast | - | - | - | - | - | $7.53M | $7.13M | $10.65M | $12.84M | $8.05M | $5.30M | $2.92M | $11.42M | $10.05M | $6.75M | $7.94M | $17.74M | $22.53M |
| Low Forecast | - | - | - | - | - | $5.02M | $4.75M | $7.10M | $17.93M | $5.37M | $7.40M | $4.08M | $15.95M | $6.70M | $4.50M | $5.29M | $24.78M | $15.02M |
| Surprise % | - | - | - | - | - | 1.36% | 1.35% | 1.07% | -1.85% | 1.39% | 1.50% | 2.78% | 0.67% | 0.78% | 1.06% | 0.94% | 0.24% | 1.08% |
Korro Bio's average Quarter SG&A projection for Dec 23 is -, based on 9 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to FREQ last annual SG&A of $10.11M (Sep 23).
Korro Bio EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 6 | 6 | 9 | 9 | 12 | 18 | 10 | 3 | 7 | 5 | 10 | 11 | 19 | 9 | 10 | 9 | 20 |
| EPS | - | - | - | - | $-0.31 | $-0.55 | $-0.61 | $-0.67 | $1.82 | $-0.73 | $-0.52 | $-0.60 | $-0.30 | $-0.16 | $-0.19 | $-0.16 | $-0.19 | $-0.02 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.29 | $-0.33 | $-0.61 | $-0.69 | $-0.66 | $-0.55 | $1.25 | $-0.51 | $-0.27 | $-0.32 | $-0.36 | $-0.22 | $-0.25 | $0.68 | $-0.63 |
| High Forecast | $1.22 | $1.06 | $1.25 | $-0.23 | $-0.33 | $-0.48 | $-0.55 | $-0.52 | $-0.44 | $0.99 | $-0.40 | $-0.21 | $-0.25 | $-0.29 | $-0.17 | $-0.20 | $0.54 | $-0.50 |
| Low Forecast | $1.86 | $1.62 | $1.90 | $-0.35 | $-0.38 | $-0.74 | $-0.83 | $-0.80 | $-0.66 | $1.50 | $-0.62 | $-0.33 | $-0.39 | $-0.43 | $-0.27 | $-0.30 | $0.82 | $-0.76 |
| Surprise % | - | - | - | - | 0.94% | 0.90% | 0.88% | 1.02% | -3.31% | -0.59% | 1.02% | 2.22% | 0.94% | 0.44% | 0.86% | 0.64% | -0.28% | 0.03% |
According to 10 Wall Street analysts, Korro Bio's projected average Quarter EPS for Mar 22 is $-0.66, with a low estimate of $-0.80 and a high estimate of $-0.52. This represents a -136.26% decrease compared to FREQ previous annual EPS of $1.82 (Dec 21).
Korro Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ONCT | Oncternal Therapeutics | $1.08 | $28.00 | 2492.59% | Buy |
| FREQ | Korro Bio | $0.30 | $7.00 | 2233.33% | Buy |
| PASG | Passage Bio | $0.48 | $6.00 | 1150.00% | Buy |
| PMVP | PMV Pharmaceuticals | $1.59 | $18.00 | 1032.08% | Buy |
| STTK | Shattuck Labs | $1.14 | $12.00 | 952.63% | Hold |
| PRLD | Prelude Therapeutics | $0.96 | $6.25 | 551.04% | Sell |
| PRTG | Portage Biotech | $4.15 | $19.50 | 369.88% | Buy |
| OLMA | Olema Pharmaceuticals | $8.72 | $28.50 | 226.83% | Buy |
| CCCC | C4 Therapeutics | $4.15 | $13.50 | 225.30% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| ADVM | Adverum Bio | $6.25 | $15.00 | 140.00% | Buy |
| KZR | Kezar Life Sciences | $7.38 | $17.50 | 137.13% | Buy |
| ABSI | Absci | $2.72 | $6.00 | 120.59% | Buy |
| SRRK | Scholar Rock | $27.86 | $40.50 | 45.37% | Buy |